Acute Respiratory Distress Syndrome, Conscious Sedation, Corona Virus Infection, Electroencephalogram, Pathologic Processes
Conditions
Brief summary
Sedation of severe COVID-19 disease are often complicated. We try to find a correlate for this observation by encephalographic studies.
Detailed description
Sedation of critically ill ventilated coronavirus patients, continues to be a challenging issue. Also, neurological symptoms of severe COVID-19 disease have been described frequently. Difficulties in sedation of these patients have been discussed repeatedly. The aim of this study is to investigate whether an encephalographic correlate can be found. Appropriate processed encephalographic techniques have been used for anesthesia monitoring for many years. The aim of our study is to collect unrelated processed and raw EEG data of sedated COVID-19 patients and to investigate the correlation to the necessary sedation.
Interventions
OTHEREncephalography measurement
Encephalography measurement and partially aggravated sedation.
Sponsors
Goethe University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Intubated ventilated patients with SARS-CoV-2 associated acute respiratory distress syndrome and sedation difficulty.
Exclusion criteria
Pre-existing severe cerebral brain damage and dysfunction. For example: previous medial infarction, cerebral hemorrhage, structural epilepsy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Raw data encephalography measurement | From the beginning of the measurement until the end of the examination (10 to 20 minutes). | Measurement of the brain activity detectable for the examination procedure in the surface encephalogram. |
| Processed encephalography measurement | From the beginning of the measurement until the end of the examination (10 to 20 minutes). | Measurement of detectable algorithm based patient sedation score based on brain activity in the surface encephalogram. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dosage of continuously administered centrally acting alpha2 agonists. | From 90 minutes before to 10 minutes after encephalographic measurement | Sedative dosage continuously administered during the measurement interval. \[µg/kg/h\] |
| Dosage of continuously delivered central GABA receptor active substances. | From 90 minutes before to 10 minutes after encephalographic measurement | Sedative dosage continuously administered during the measurement interval. \[mg/kg/h\] |
| Dosage of continuously delivered central NMDA receptor active substances. | From 90 minutes before to 10 minutes after encephalographic measurement | Sedative dosage continuously administered during the measurement interval. \[mg/kg/h\] |
| Dosage of continuously delivered opioid based analgesia. | From 90 minutes before to 10 minutes after encephalographic measurement | Analgetic dosage continuously administered during the measurement interval. \[µg/kg/h\] |
Countries
Germany
Outcome results
None listed